Product Details

Veronda is a sterile injectable formulation that meets British Pharmacopoeia (BP) standards. Specifically, it delivers Ondansetron (as Ondansetron Hydrochloride BP) for use as a potent antiemetic through the intramuscular (I.M.) or intravenous (I.V.) route. As a result, it offers fast, reliable relief from nausea and vomiting in a range of clinical settings.

The injection contains:

• Ondansetron (as Ondansetron Hydrochloride BP) – A selective 5-HT3 receptor antagonist that blocks serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract. Consequently, it prevents the nausea and vomiting signals triggered by chemotherapy, radiotherapy, surgery, and other emetogenic stimuli.

Physicians use Veronda for the prevention and treatment of nausea and vomiting associated with cytotoxic chemotherapy, radiotherapy, and post-operative recovery. In addition, its dual-route (I.M./I.V.) formulation allows flexible administration based on clinical setting and patient need. Because of this profile, Veronda suits hospitals, oncology units, and surgical care settings where reliable antiemetic control is essential.

Key Features:

• Overall, this BP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the dual-route (I.M./I.V.) formulation offers flexible clinical use
• Furthermore, each vial delivers precise, validated dosage accuracy
• Notably, rigorous purity and sterility testing backs every stage of manufacturing
• Beyond that, light-protected vial packaging preserves product stability during storage
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, oncology units, and pharmacies